ERLANGER Home
MyErlangerHealth HealthLink Plus For Vendors For the Media Physician Relations and Recruitment
975 East Third Street
Chattanooga, TN 37403
423-778-7000
Children's Hospital at Erlanger Erlanger Baroness Campus Erlanger Bledsoe Campus Erlanger East Campus Erlanger North Campus UT Erlanger Physicians Group





Online Prereg
Register for a Class or Event
New Foundations Page
Print   Email

Lung

 

Non-Small Cell Lung Carcinoma

E1505                                Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) (IRB#: 07-087 )

NCT #: NCT00324805        Phase: Phase III

Purpose:This randomized phase III trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery.

Drugs possibly given:
Bevacizumab
Cisplatin
Docetaxel
Gemcitabine hydrochloride
Pemetrexed disodium
Vinorelbine tartrate

 Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT00324805?term=E1505&rank=1